Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere-targeting anticancer drug development.
We previously reported that the telomere-targeting drug telomestatin induces apoptosis accompanied by G-tail reduction and dissociation of binding protein TRF2 from telomeres in cancer cell lines but not normal or human telomerase reverse transcriptase (hTERT)-immortalized cells. Because telomere-targeting drugs induce growth arrest in normal cells at higher doses, their development is dependent on the ability to predict toxicity before in vivo use, but no models for this are available. Here, we established two new cell lines, telomerase immortalized human fetal hepatocytes, Hc3716-hTERT, and telomerase immortalized hepatic stellate cells, NPC-hTERT. Examinations showed that Hc3716-hTERT maintained normal mammalian cell morphology, cell growth, albumin expression, and wild-type p53 responsiveness, whereas NPC-hTERT maintained hepatic stellate-like morphology, expression of hepatic stellate markers, alpha-smooth muscle actin, and secretion of type I collagen, an extracellular matrix protein. Given our finding that telomere G-tail length in Hc3716 cells was decreased in senescence and increased by hTERT infection, we next examined the effect of high-dose telomestatin-induced telomere dysfunction and G-tail shortening on cellular functions in Hc3716-hTERT cells. Interestingly, telomestatin decreased expression of cytochrome P450 (CYP) family members CYP3A3/4, CYP3A5, and CYP3A7, mRNA and induced albumin expression at both mRNA and protein levels. These gene expression responses to telomestatin were similar to those of the normal parental cell Hc3716. These established cell lines thus represent the first model for predicting the side-effects of telomere-targeting drugs in normal cells, and should be powerful tools in the development of these drugs.
Waki
Koji
K
Division of Frontier Medical Science Programs for Biomedical Research, Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Anno
Kumiko
K
Ono
Taeko
T
Ide
Toshinori
T
Chayama
Kazuaki
K
Tahara
Hidetoshi
H
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000633:toxicity; D002455:Cell Division; D045744:Cell Line, Tumor; D005333:Fetus; D005784:Gene Amplification; D055166:Hepatic Stellate Cells / Q000187:drug effects / Q000201:enzymology*; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology* / Q000821:virology; D006801:Humans; D010080:Oxazoles / Q000494:pharmacology / Q000633:toxicity; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D012333:RNA, Messenger / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019098:Telomerase / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D016615:Telomere / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D014161:Transduction, Genetic
D000970:Antineoplastic Agents; D010080:Oxazoles; D012333:RNA, Messenger; C431888:telomestatin; D012313:RNA; C509186:TERT protein, human; D019098:Telomerase
Nat Rev Mol Cell Biol. 2004 Apr;5(4):323-9
15071557
Hepatology. 2003 Nov;38(5):1095-106
14578848
Semin Liver Dis. 2001 Aug;21(3):351-72
11586465
Nat Genet. 1998 Jan;18(1):65-8
9425903
Science. 1998 Jan 16;279(5349):349-52
9454332
Arch Biochem Biophys. 1985 Aug 15;241(1):275-80
4026319
Biochem Biophys Res Commun. 1999 Mar 5;256(1):184-91
10066444
Mol Cell Biol. 2005 Mar;25(6):2158-68
15743814
Gastroenterology. 2003 Feb;124(2):432-44
12557149
Biochem Biophys Res Commun. 2007 Feb 23;353(4):926-32
17207773
Arch Biochem Biophys. 1989 Jan;268(1):144-51
2492179
Oncogene. 2002 Jan 21;21(4):532-40
11850778
Oncogene. 2006 Mar 23;25(13):1955-66
16302000
Nat Methods. 2005 Nov;2(11):829-31
16278652
Nat Genet. 2003 Apr;33(4):492-6
12652299
Cell. 1982 May;29(1):245-55
6286143
Lab Invest. 2002 Jun;82(6):719-28
12065682
Semin Liver Dis. 2001 Aug;21(3):337-49
11586464
Annu Rev Biochem. 1996;65:337-65
8811183
Cell. 1997 Mar 7;88(5):657-66
9054505
Gut. 2005 Jan;54(1):142-51
15591520
J Am Chem Soc. 2001 Feb 14;123(6):1262-3
11456694
Cancer Res. 1995 Jul 1;55(13):2734-6
7796395
Clin Chem. 1999 Oct;45(10):1718-24
10508116
FASEB J. 1999 Nov;13(14):1883-900
10544172
Cell Transplant. 2008 Sep;17(9):1083-1094
28863749
Oncogene. 2003 Aug 14;22(34):5338-47
12917635
Lab Invest. 1995 Jun;72(6):731-9
7540235
J Biol Chem. 2000 Jan 28;275(4):2247-50
10644669
Science. 1997 Aug 15;277(5328):955-9
9252327
J Clin Invest. 1990 Nov;86(5):1641-8
2243137